^
Association details:
| Biomarker: | EGFR L858R + ALK R1275Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-044 Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC
Published date:
07/12/2022
Excerpt:
An 80-year-old woman, smoker, with COPD and reduced lung capacity, in PS 2, was diagnosed with T3bN1M0 NSCLC...new cfDNA analysis showed acquired activating ALK p.R1275Q mutation in the ALK-TK-domain….Thus, Alectinib in reduced dose was initiated while continuing Osimertinib in reduced dose, due to the patient’s fragile status. The treatment was well tolerated with no adverse events and improved quality of life. Three subsequent CT-scans of chest/abdomen showed stable disease...
